287 related articles for article (PubMed ID: 34549727)
1. Germline mutations in a DNA repair pathway are associated with familial colorectal cancer.
Xu P; Sun D; Gao Y; Jiang Y; Zhong M; Zhao G; Chen J; Wang Z; Liu Q; Hong J; Chen H; Chen YX; Fang JY
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34549727
[TBL] [Abstract][Full Text] [Related]
2. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.
Yurgelun MB; Kulke MH; Fuchs CS; Allen BA; Uno H; Hornick JL; Ukaegbu CI; Brais LK; McNamara PG; Mayer RJ; Schrag D; Meyerhardt JA; Ng K; Kidd J; Singh N; Hartman AR; Wenstrup RJ; Syngal S
J Clin Oncol; 2017 Apr; 35(10):1086-1095. PubMed ID: 28135145
[TBL] [Abstract][Full Text] [Related]
3. The Fanconi anemia DNA damage repair pathway in the spotlight for germline predisposition to colorectal cancer.
Esteban-Jurado C; Franch-Expósito S; Muñoz J; Ocaña T; Carballal S; López-Cerón M; Cuatrecasas M; Vila-Casadesús M; Lozano JJ; Serra E; Beltran S; Brea-Fernández A; Ruiz-Ponte C; Castells A; Bujanda L; Garre P; Caldés T; Cubiella J; Balaguer F; Castellví-Bel S
Eur J Hum Genet; 2016 Oct; 24(10):1501-5. PubMed ID: 27165003
[TBL] [Abstract][Full Text] [Related]
4. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
5. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical findings and clinicopathological features of breast cancers with pathogenic germline mutations in Non-BRCA genes.
Singh K; Scalia J; Legare R; Quddus MR; Sung CJ
Hum Pathol; 2024 Apr; 146():49-56. PubMed ID: 38608781
[TBL] [Abstract][Full Text] [Related]
7. Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline
Thibodeau ML; Reisle C; Zhao E; Martin LA; Alwelaie Y; Mungall KL; Ch'ng C; Thomas R; Ng T; Yip S; J Lim H; Sun S; Young SS; Karsan A; Zhao Y; Mungall AJ; Moore RA; J Renouf D; Gelmon K; Ma YP; Hayes M; Laskin J; Marra MA; Schrader KA; Jones SJM
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28514723
[TBL] [Abstract][Full Text] [Related]
8. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
9. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
10. Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer.
Paulo P; Maia S; Pinto C; Pinto P; Monteiro A; Peixoto A; Teixeira MR
PLoS Genet; 2018 Apr; 14(4):e1007355. PubMed ID: 29659569
[TBL] [Abstract][Full Text] [Related]
11. Profiling of the genetic features of patients with breast, ovarian, colorectal and extracolonic cancers: Association to CHEK2 and PALB2 germline mutations.
Infante M; Arranz-Ledo M; Lastra E; Olaverri A; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
Clin Chim Acta; 2024 Jan; 552():117695. PubMed ID: 38061684
[TBL] [Abstract][Full Text] [Related]
12. Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing.
Chubb D; Broderick P; Frampton M; Kinnersley B; Sherborne A; Penegar S; Lloyd A; Ma YP; Dobbins SE; Houlston RS
J Clin Oncol; 2015 Feb; 33(5):426-32. PubMed ID: 25559809
[TBL] [Abstract][Full Text] [Related]
13.
Stolarova L; Kleiblova P; Janatova M; Soukupova J; Zemankova P; Macurek L; Kleibl Z
Cells; 2020 Dec; 9(12):. PubMed ID: 33322746
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic characteristics of FBXW7-mutated colorectal adenocarcinoma and association with aberrant beta-catenin localization.
Escobar D; Bushara O; Sun L; Liao J; Yang GY
Hum Pathol; 2022 Jan; 119():51-58. PubMed ID: 34717891
[TBL] [Abstract][Full Text] [Related]
15. Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy.
Rizzolo P; Zelli V; Silvestri V; Valentini V; Zanna I; Bianchi S; Masala G; Spinelli AM; Tibiletti MG; Russo A; Varesco L; Giannini G; Capalbo C; Calistri D; Cortesi L; Viel A; Bonanni B; Azzollini J; Manoukian S; Montagna M; Peterlongo P; Radice P; Palli D; Ottini L
Int J Cancer; 2019 Jul; 145(2):390-400. PubMed ID: 30613976
[TBL] [Abstract][Full Text] [Related]
16. Whole-Exome Sequencing Identifies a Novel Germline Variant in
Miao B; Skopelitou D; Srivastava A; Giangiobbe S; Dymerska D; Paramasivam N; Kumar A; Kuświk M; Kluźniak W; Paszkowska-Szczur K; Schlesner M; Lubinski J; Hemminki K; Försti A; Bandapalli OR
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163215
[TBL] [Abstract][Full Text] [Related]
17. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
[TBL] [Abstract][Full Text] [Related]
18. Whole Genome Sequencing Prioritizes
Srivastava A; Giangiobbe S; Skopelitou D; Miao B; Paramasivam N; Diquigiovanni C; Bonora E; Hemminki K; Försti A; Bandapalli OR
Front Endocrinol (Lausanne); 2021; 12():600682. PubMed ID: 33692755
[TBL] [Abstract][Full Text] [Related]
19. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
Alter BP; Best AF
Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
[TBL] [Abstract][Full Text] [Related]
20. Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer.
Rummel SK; Lovejoy L; Shriver CD; Ellsworth RE
Breast Cancer Res Treat; 2017 Aug; 164(3):593-601. PubMed ID: 28503720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
